Moreno J, Caplan A L, Wolpe P R
Center for Bioethics, University of Pennsylvania Health System, Philadelphia 19104-3308, USA.
JAMA. 1998 Dec 9;280(22):1951-8. doi: 10.1001/jama.280.22.1951.
For decades, all federally funded research involving human subjects has been subject to regulations that require the informed consent of the subject and oversight by the local institution. These regulations last underwent major revision in 1981 and have remained unchanged despite significant changes in the nature of clinical science, the financial sources of research support, and the institutional environment in which clinical research is conducted. In the intervening years, doubt has evolved as to whether the regulations currently in place adequately protect the welfare and rights of research subjects in today's clinical research environment and whether the costs, in terms of time, bureaucracy, and delay, are justified by the level of protection afforded. The Human Research Ethics Group, administered by the Center for Bioethics at the University of Pennsylvania Health System, extensively reviewed the status of existing human subjects protections with the aim of making recommendations to improve and reform the regulations. Here, we present recommendations constituting a consensus of the group members for reform in 3 key areas: protecting subject populations with special needs and vulnerabilities, oversight by institutional review boards, and regulatory policy.
几十年来,所有由联邦政府资助的涉及人类受试者的研究都要遵守相关规定,这些规定要求受试者知情同意并接受当地机构的监督。这些规定上次进行重大修订是在1981年,尽管临床科学的性质、研究支持的资金来源以及开展临床研究的机构环境发生了重大变化,但这些规定一直未变。在这期间,人们逐渐怀疑现行规定是否能在当今的临床研究环境中充分保护研究受试者的福利和权利,以及在时间、官僚作风和延误方面的成本是否与所提供的保护水平相称。由宾夕法尼亚大学医疗系统生物伦理中心管理的人类研究伦理小组对现有的人类受试者保护状况进行了广泛审查,目的是提出改进和改革这些规定的建议。在此,我们提出构成小组成员在三个关键领域改革共识的建议:保护有特殊需求和易受伤害的受试者群体、机构审查委员会的监督以及监管政策。